Republicans have seized control of federal cannabis policy, advancing legislation on workplace protections, hemp standards, and psychedelic research while Democrats lack a coordinated response. The shift marks a significant departure from decade-long Democratic efforts to lead legalization efforts, revealing how quickly political momentum can reverse when one party abandons rhetorical consistency for regulatory pragmatism.
That may be the most uncomfortable fact in cannabis policy right now. And for the patients, equity advocates, and expungement organizers who spent years pushing Democrats toward legalization, it’s starting to feel personal.
The Ground Has Shifted
There’s no tidy narrative about Republicans becoming the cannabis party. But there’s a real and growing pattern.
At the state level, Republican-controlled legislatures in Montana, Mississippi, and Missouri have all expanded their medical programs in recent cycles. Oklahoma, one of the reddest states in the country, built what became one of the nation’s most accessible medical marijuana systems — open licensing, low barriers, broad qualifying conditions. When a new employer-protection bill crossed Gov. Kevin Stitt’s desk last week, he signed it.
At the federal level, it’s more complicated. Trump’s move on psychedelics wasn’t about cannabis — it was about veterans, PTSD, and a base that increasingly includes people who’ve lost family members to mental health crises. But the political effect is the same: a Republican president is now associated with expanded drug access, harm reduction, and medical legitimacy for substances long categorized as dangerous.
Meanwhile, Democratic leadership has largely gone quiet. The party that ran on decriminalization in 2020, that held hearings and sponsored federal legislation and had candidates lighting joints on Instagram, has been almost invisible on cannabis in 2025 and 2026. The SAFE Banking Act passed committee on a party-line vote earlier this month, and even that small procedural win was framed as a policy concession rather than a values statement.
The Bipartisan Hemp Moment — and What It Exposes
Last week’s Senate bill to preserve state hemp authority is being read in two ways.
Industry advocates see it as a lifeline: the FDA and DEA have been moving toward a federal framework that could effectively ban or severely restrict hemp-derived THC products — the same drinks, gummies, and tinctures that make up a fast-growing consumer market and provide a legal pathway for cannabis access in non-legal states. The bill would maintain the current patchwork of state authority, buying time for a more coherent federal framework to emerge.
What’s notable is who’s pushing it. The lead sponsors include members from both parties, but the impetus came partly from hemp-state Republicans who represent farmers and rural processors. Their motivation isn’t ideological — it’s constituent services. Their farmers grow it. Their rural communities depend on it.
For cannabis advocates who spent years trying to build bipartisan support for equity-focused federal legalization, watching Republicans quietly absorb the hemp issue through a farm lens is instructive, and a little maddening.
“The hemp conversation is becoming a Republican conversation because hemp is an agricultural product,” said one cannabis policy researcher who has worked with both parties. “And the agricultural conversation is a Republican conversation. The equity and expungement piece has no natural Republican champion. That’s where Democrats keep dropping the ball.”
What Expungement Advocates Are Saying
If there’s one issue that clearly belongs to the left and keeps not moving, it’s expungement.
More than 40,000 people are still incarcerated for federal cannabis offenses. Millions more carry state convictions — for possession, distribution, cultivation — that follow them through job applications, housing eligibility, professional licensing, child custody proceedings. Some of those convictions date back decades, for conduct that is now legal in most of the country.
Several states have made genuine progress: California’s automated expungement program has cleared hundreds of thousands of records. Illinois built automatic relief directly into its legalization statute. New York has done the same. But the pace is uneven, implementation has been slow, and federal records — which fall outside state jurisdiction — remain untouched.
The Biden administration used clemency broadly but selectively, commuting sentences for some low-level federal cannabis offenders in the final months of the presidency. The Trump administration has shown no interest in the issue.
What advocates expected was that Democrats, freed from the pressure of governing, would recommit to expungement as a core party position — and use the 2026 cycle to make Republicans vote against it. That hasn’t happened.
“We’ve been waiting for someone to introduce the clean federal expungement bill, bring it to the floor, and make it a vote,” one national reform organizer told me. “Not because it’ll pass. But because forcing a recorded vote is how you build toward 2028. They’re not doing it.”
The Medical Patient Angle That Gets Overlooked
There’s another population watching this political drift with particular frustration: medical marijuana patients in states that still don’t have adult-use access, or that have medical programs that function poorly.
Pennsylvania’s medical program, for example, has over 400,000 registered patients. A new bill introduced this week — SB1274 — would expand the medical exemptions and clarify definitions for qualifying conditions. But the broader legislative conversation in Harrisburg has been stalled for years. Adult-use legalization has passed one chamber and died in committee. New Jersey, just next door, has a functioning adult-use market.
For a patient with a chronic pain condition in rural Pennsylvania, the politics of which party owns the cannabis narrative isn’t an abstraction. It’s about whether they drive an hour to a dispensary or buy from the unregulated market because the licensed stores near them have limited product and high prices.
“I keep voting for people who say they support this,” said one patient I spoke with, who has used medical cannabis to manage a neurological condition since 2019. “And then nothing changes at the federal level. The taxes don’t change. The banking doesn’t change. My employer can still test me and fire me in certain situations. The politics feel very far away from my actual life.”
What the 2026 Cycle Could Look Like
The argument in The Hill’s op-ed is fundamentally electoral: Democrats are leaving votes on the table by treating cannabis as a third-tier issue, and they’re creating an opening for Republicans who are willing to speak the language of access and medical freedom.
The data is consistent. Gallup polling puts support for federal legalization at nearly 70%. That support cuts across age groups and increasingly across party lines. In competitive House and Senate races in states like Pennsylvania, Georgia, Wisconsin, and Arizona, cannabis legalization is a marginal but real factor for persuadable voters — particularly younger ones and suburban moderates.
The counterargument from some Democratic strategists is that cannabis is not a top-five issue for most voters, and running on it invites attacks on crime and public safety. That calculation made sense in 2002. It’s harder to defend in 2026, when recreational cannabis is legal in 24 states and the majority of Americans can buy it legally closer to their homes than they can buy a glass of wine.
What’s missing isn’t public support. It’s political will — specifically, the willingness to make cannabis part of a coherent values argument about who government works for, and to force uncomfortable votes before any election rather than waiting to see how the polling looks.
The Equity Question Won’t Wait Forever
Cannabis social equity programs are failing in slow motion across the country. Not because the concept is wrong — it isn’t — but because the implementation has been left to states with varying degrees of political will, administrative capacity, and legal support.
Illinois’s program, often cited as a model, has produced meaningful results and ongoing lawsuits. California’s equity framework has been undermined by local permitting delays and tax burdens that make licensed equity operators less competitive than unlicensed sellers. New York’s rollout has been litigated into near-paralysis.
At the federal level, there’s no equity program because there’s no federal framework. That means the people most harmed by prohibition — disproportionately Black and Latino communities — remain locked out of an industry whose wealth is concentrating in familiar places.
This is the argument that the advocates quoted in The Hill’s piece are making: that ceding the cannabis issue to Republicans isn’t just politically reckless, it’s a moral abdication. The communities that bore the cost of the War on Drugs are still waiting for its end. They’re not waiting for the party that promises them the most. They’re waiting for the party that promised them something to actually deliver.
That’s a more complicated political message than “Trump is bad on cannabis.” But it’s the truer one. And on 4/20 of an election year, it’s worth saying out loud.
Maya Torres covers cannabis policy, equity, and the human stakes of legalization for CannabisInquirer.com.
Responses